|
Developed by
|
Supported by
|
|
ViiV Healthcare Originator
https://viivhealthcare.com/
United Kingdom ViiV Healthcare is a pharmaceutical company that specializes in the development of therapies for HIV infection. The company is headquartered in Brentford in the United Kingdom and was initially formed in November 2009 as a part of a joint venture between GlaxoSmithKline and Pfizer. |

Cabotegravir Chemical Structure
Sourced from DrugBank
Aqueous drug particle suspension
Oral, Intramuscular
600 mg/3 mL
200 mg/mL
Not provided
Not provided
Not provided
No delivery device
Compound is commercially manufactured by the innovator and three generic manufacturers have received a licence through the medicines patent pool to manufacture generic versions by 2026/2027.
Conventional wet-bead milling (ball mill), depyrogenated glass vials.
Cabotegravir is subject to a gamma-irradiation pre-sterilization step prior to a conventional wet-bead milling manufacturing procedure. The Cabotegravir milling process is initiated alongside pharmaceutical excipients (polyethylene glycol 3350, water for injection, polysorbate 20 and mannitol) for an overall 200nm drug particle size. Sterilized de-pyrogenated glass vials are used to store the finished drug nanosuspension, before an additional gamma irradiation (25kGy) step to ensure aseptic packaging conditions.
PANalytical X’Pert PRO diffractometer equipped with a theta/theta coupled goniometer (or equivalent x-ray powder diffractor) to determine drug particle size, Mettler TGA/DSC 1 instrument for thermal analysis, HPLC to evaluate drug content, impurities and dissolution, HPLC UV-Vis Detector for drug identification.
NCT02076178
https://clinicaltrials.gov/study/NCT02076178
Phase II
Completed
ViiV Healthcare
This study is a Phase IIa, randomized, multi-site, two-arm, double-blinded study to evaluate the safety, tolerability, and acceptability of GSK1265744 long acting injectable formulation (744 LA) in adult male subjects. To evaluate the safety and tolerability of the injectable agent, 744 LA (800 milligrams (mg) dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men. Eligible participants will be randomized in a 5:1 ratio to receive 744 LA or matching placebo. Participants will receive daily oral 744 (30 mg tablets) or matching placebo for 4 weeks during the Oral Phase of the study, followed by a one week washout period. Following safety lab assessments from the Oral Phase, participants will enter the Injection Phase and receive Intramuscular (IM)
Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2014-03-27
Anticipated Date of Last Follow-up
2017-12-13
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2015-05-15
Actual Completion Date
2016-02-23
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: * Non-reactive HIV test at screening or enrollment. * Males 18 to 65 years old at the time of signing the informed consent. * At risk of acquiring HIV, defined as having at least one casual sex partner in the past 24 months. * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring at the time of screening. * If participating in sexual activity with a female of child-bearing potential, men must agree to use condoms. Subjects who are sexual partners of females with child bearing potential must also agree to practice an acceptable method of contraception for the duration of the study, such as double barrier (male condom/spermicide, male condom/
Interventional (clinical trial)
127
Randomized
Parallel Assignment
Not provided
Double-blind masking
Double (Participant, Investigator)
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial | https://pubmed.ncbi.nlm.nih.gov/30445896/ | |
| Link | Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial | https://pubmed.ncbi.nlm.nih.gov/28546090/ |
NCT02178800
https://clinicaltrials.gov/study/NCT02178800
Phase II
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
This study will evaluate the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2015-02-01
Anticipated Date of Last Follow-up
2021-10-14
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2017-04-05
Actual Completion Date
2018-07-13
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * Men and women, 18 to 65 years old at the time of screening * Willing to provide informed consent for the study * In the last 12 months (at the time of screening): * No self-reported unprotected anal or vaginal intercourse with someone known to be HIV-infected or of unknown HIV infection status * No self-reported stimulant use (cocaine \[including crack\], methamphetamine, or non-physician-prescribed pharmaceutical-grade stimulants) or inhaled nitrate * No self-reported illicit injection drug use of any kind * No self-reported diagnosis of gonorrhea (GC), chlamydia (CT), incident syphilis, bacterial vaginosis, or trichomoniasis * Not reporting five or more different sexual partners, regardless of use of protection or knowledge of HIV status. More informatio
Interventional (clinical trial)
199
Randomized
Parallel Assignment
Not provided
Quadruple-blind masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial | https://pubmed.ncbi.nlm.nih.gov/32497491/ | |
| Link | Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial | https://pubmed.ncbi.nlm.nih.gov/30408115/ |
NCT02720094
https://clinicaltrials.gov/study/NCT02720094
Phase II/III
Completed
National Institute of Allergy and Infectious Diseases
Not provided
Evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men.
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2016-12-19
Anticipated Date of Last Follow-up
2026-03-18
Estimated Primary Completion Date
Not provided
Estimated Completion Date
2025-04-30
Actual Primary Completion Date
2020-05-14
Actual Completion Date
2025-03-31
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
HIV negative cis-gender men and transgender women (18 years or older at the time of screening [assigned male at birth]) who have sex with men and at high risk of HIV infection.
Interventional (clinical trial)
4570
Randomized
Parallel Assignment
Not provided
Quadruple-blind masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women | https://pubmed.ncbi.nlm.nih.gov/34379922/ | |
| Publication | Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. | Background: Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) compared with tenofovir disoproxil fumarate plus emtricitabine daily oral PrEP. Long-acting PrEP was associated with diagnostic delays and integrase strand-transfer inhibitor (INSTI) resistance. This report presents findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study.Methods: The HPTN 083 randomised controlled trial enrolled HIV-uninfected cisgender men and transgender women at elevated HIV risk who have sex with men, from 43 clinical research sites in Africa, Asia, Latin America, and the USA. Inclusion criteria included: a negative HIV serological test at the screening and study entry, undetectable HIV RNA levels within 14 days of study entry, age 18 years or older, overall good health as determined by clinical and laboratory evaluations, and a creatinine clearance of 60 mL/min or higher. Participants were randomly allocated to receive long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP. After study unblinding, participants remained on their original regimen awaiting an extension study. HIV infections were characterised retrospectively at a central laboratory. Here we report the secondary analysis of efficacy and safety for the first unblinded year. The primary outcome was incident HIV infection. Efficacy analyses were done on the modified intention-to-treat population using a Cox regression model. Adverse events were compared across treatment groups and time periods (blinded vs unblinded). This trial is registered with ClinicalTrials.gov, NCT02720094.Findings: Of the 4488 participants who contributed person-time to the blinded analysis, 3290 contributed person-time to the first unblinded year analysis between May 15, 2020, and May 14, 2021. Updated HIV incidence in the blinded phase was 0·41 per 100 person-years for long-acting injectable cabotegravir PrEP and 1·29 per 100 person-years for daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP (hazard ratio [HR] 0·31 [95% CI 0·17-0·58], p=0·0003). HIV incidence in the first unblinded year was 0·82 per 100 person-years for long-acting PrEP and 2·27 per 100 person-years for daily oral PrEP (HR 0·35 [0·18-0·69], p=0·002). Adherence to both study products decreased after study unblinding. Additional infections in the long-acting PrEP group included two with on-time injections; three with one or more delayed injections; two detected with long-acting PrEP reinitiation; and 11 more than 6 months after their last injection. Infection within 6 months of cabotegravir exposure was associated with diagnostic delays and INSTI resistance. Adverse events were generally consistent with previous reports; incident hypertension in the long-acting PrEP group requires further investigation.Interpretation: Long-acting injectable cabotegravir PrEP retained high efficacy for HIV prevention in men and transgender women who have sex with men during the first year of open-label follow-up, with a near-identical HR for HIV risk reduction between long-acting injectable cabotegravir and daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP during the first year after unblinding compared with the blinded period. Extended follow-up further defined the risk period for diagnostic delays and emergence of INSTI resistance. | https://pubmed.ncbi.nlm.nih.gov/37952550/ |
NCT03164564
https://clinicaltrials.gov/study/NCT03164564
Phase III
Active, not recruiting
National Institute of Allergy and Infectious Diseases (NIAID)
This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2017-11-07
Anticipated Date of Last Follow-up
2025-09-23
Estimated Primary Completion Date
Not provided
Estimated Completion Date
2026-10-17
Actual Primary Completion Date
2020-11-05
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * Born female * 18-45 years at the time of screening * Willing and able to provide informed consent * Willing and able to undergo all required study procedures * Non-reactive HIV test results at Screening and Enrollment. Note: HIV-uninfected, based on HIV test results obtained at Screening and just prior to randomization at the Enrollment visit. All HIV test results from the Screening visit must be obtained and must all be negative/non-reactive. This includes testing for acute HIV infection, which must be performed within 14 days of Enrollment. In addition, at least one HIV test result using blood drawn at the Enrollment visit must be obtained prior to randomization into the study and must be negative/non-reactive. Individuals who have one or more reactive or positive
Interventional (clinical trial)
3224
Randomized
Parallel Assignment
Not provided
Quadruple-blind masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial | https://pubmed.ncbi.nlm.nih.gov/35378077/ | |
| Publication | Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial | Background: Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and the fear of violence. Safe and effective long-acting agents for HIV prevention are needed for women. We aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women.Methods: HPTN 084 was a phase 3, randomised, double-blind, double-dummy, active-controlled, superiority trial in 20 clinical research sites in seven countries in sub-Saharan Africa. Participants were eligible for enrolment if they were assigned female sex at birth, were aged 18-45 years, reported at least two episodes of vaginal intercourse in the previous 30 days, were at risk of HIV infection based on an HIV risk score, and agreed to use a long-acting reversible contraceptive method. Participants were randomly assigned (1:1) to either active cabotegravir with TDF-FTC placebo (cabotegravir group) or active TDF-FTC with cabotegravir placebo (TDF-FTC group). Study staff and participants were masked to study group allocation, with the exception of the site pharmacist who was responsible for study product preparation. Participants were prescribed 5 weeks of daily oral product followed by intramuscular injections every 8 weeks after an initial 4-week interval load, alongside daily oral pills. Participants who discontinued injections were offered open-label daily TDF-FTC for 48 weeks. The primary endpoints of the study were incident HIV infection in the intention-to-treat population, and clinical and laboratory events that were grade 2 or higher in all women who had received at least one dose of study product. This study is registered with ClinicalTrials.gov, NCT03164564.Findings: From Nov 27, 2017, to Nov 4, 2020, we enrolled 3224 participants (1614 in the cabotegravir group and 1610 in the TDF-FTC group). Median age was 25 years (IQR 22-30); 1755 (54·7%) of 3209 had two or more partners in the preceding month. 40 incident infections were observed over 3898 person-years (HIV incidence 1·0% [95% CI 0·73-1·40]); four in the cabotegravir group (HIV incidence 0·2 cases per 100 person-years [0·06-0·52]) and 36 in the TDF-FTC group (1·85 cases per 100 person-years [1·3-2·57]; hazard ratio 0·12 [0·05-0·31]; p<0·0001; risk difference -1·6% [-1·0% to -2·3%]. In a random subset of 405 TDF-FTC participants, 812 (42·1%) of 1929 plasma samples had tenofovir concentrations consistent with daily use. Injection coverage was 93% of the total number of person-years. Adverse event rates were similar across both groups, apart from injection site reactions, which were more frequent in the cabotegravir group than in the TDF-FTC group (577 [38·0%] of 1519 vs 162 [10·7%] of 1516]) but did not result in injection discontinuation. Confirmed pregnancy incidence was 1·3 per 100 person-years (0·9-1·7); no congenital birth anomalies were reported.Interpretation: Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women. |
NCT05514509
https://clinicaltrials.gov/study/NCT05514509
Marketed
Completed
ViiV Healthcare
Not provided
Evaluate implementation strategies for the delivery of CAB for HIV PrEP across clinical settings for adult (≥18 Years) black cis-and transgender women without HIV infection living in the United States
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2022-10-28
Anticipated Date of Last Follow-up
2026-02-04
Estimated Primary Completion Date
2025-08-29
Estimated Completion Date
2025-08-29
Actual Primary Completion Date
2025-09-02
Actual Completion Date
2025-09-02
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion criteria: - Participant must be ≥18 years of age, at the time of signing the informed consent. - HIV negative at screening. Type of HIV-1 test is per standard of care. - No prior history of receiving oral CAB or CAB LA injections. - PrEP provider deems CAB PrEP use to be appropriate per the applicable CAB PrEP prescribing information prior to enrollment in the study. - Female at birth or self-identified Transgender Female. - Self-identified as African American/Black. - Capable of giving signed informed consent.
Interventional (clinical trial)
370
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
PrEP
HIV
NCT05374525
https://clinicaltrials.gov/study/NCT05374525
Marketed
Completed
ViiV Healthcare
Not provided
Evaluate implementation strategies for the delivery of cabotegravir PrEP for HIV uninfected MSM and transgender men ≥ 18 in the United States.
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2022-05-18 00:00:00
Anticipated Date of Last Follow-up
2025-01-09 00:00:00
Estimated Primary Completion Date
2024-09-06 00:00:00
Estimated Completion Date
2024-09-06 00:00:00
Actual Primary Completion Date
2024-08-08 00:00:00
Actual Completion Date
2024-08-08 00:00:00
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Not provided
Interventional (clinical trial)
201
Randomized
Parallel Assignment
Not provided
Open label
None (Open Label)
PrEP
HIV
NCT05515770
https://clinicaltrials.gov/study/NCT05515770
Phase III
Unknown status
Evandro Chagas National Institute of Infectious Disease
Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation strategies. The proposed implementation study will assess the safety and effectiveness of open label CAB LA PrEP when offered at public health facilities to cisgender men and transgender or gender non-binary individuals who have sex with persons assigned male at birth. The study will also evaluate two nested implementation strategies, an mHealth education and decision support tool and a WhatsApp injection appointment reminder. The study will also assess overall facilitators and barriers to integrating CAB LA into existing oral PrEP services.
The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir
Intervention 1
Not provided
Anticipated Start Date
2022-09-20
Actual Start Date
2022-09-20
Anticipated Date of Last Follow-up
2024-10-03
Estimated Primary Completion Date
2025-10-01
Estimated Completion Date
2026-02-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: 1. Cisgender men, non-binary (assigned as male at birth) or transgender women and men 2. Report having anal sex with a person assigned male at birth in the last six months (Persons born female having sex only with other persons born female are excluded) 3. Age 18-30 years 4. Seek a study clinic looking for PrEP 5. CAB LA and TDF/FTC PrEP naïve 6. Willing and able to provide written informed consent and adhere to the study requirements 7. Non-reactive / negative HIV test results, including both HIV rapid tests and an undetectable HIV RNA at enrollment for individuals choosing injectable CAB-LA. 8. No report of hepatic dysfunction. Candidates reporting liver disease will have their enrollment visit postponed until laboratory results of liver function are available. Indiv
Interventional (clinical trial)
1200
Not provided
Single group assignment
Methods include qualitative (focus group discussion and in-depth interviews) and quantitative (service statistics, laboratory tests, surveys) approaches. The incidence of HIV in the CAB LA study cohort will be evaluated against a similar cohort receiving oral PrEP. Interrupted time series analysis will be utilised to assess the effectiveness of the mHealth intervention.
Open label
None (Open Label)
PrEP
HIV
NCT05549726
https://clinicaltrials.gov/study/NCT05549726
Marketed
Completed
University of California, San Francisco
The overall purpose of this SEARCH CAB-LA (Cabotegravir Injectable Suspension) randomized extension study is to determine if adding the option of CAB-LA as a prevention choice using a person-centered dynamic choice HIV (human immunodeficiency virus) prevention model, with option to switch products over time, compared to the standard of care: 1) increases prevention coverage; 2) reduces HIV incident infection; and 3) increases prevention coverage during periods of self-assessed risk of HIV infection, in three settings in rural Uganda and Kenya. In addition, this study will describe implementation of a person-centered model for dynamic choice HIV prevention including CAB-LA, using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) evaluation framework among persons
SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-01-02
Anticipated Date of Last Follow-up
2026-09-01
Estimated Primary Completion Date
Not provided
Estimated Completion Date
2025-01-01
Actual Primary Completion Date
2023-12-18
Actual Completion Date
2025-01-30
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: Inclusion criteria for the Extension include: 1. Enrollment in a SEARCH Sapphire Dynamic prevention study (NCT04810650) 2. HIV negative at start of extension 3. Residing in study region Additional inclusion criteria to access CAB-LA as a prevention option 1. Not pregnant or breastfeeding at time of initial CAB-LA injection 2. Participant weighs at least 35kg Exclusion Criteria: Exclusion criteria to access CAB-LA as a prevention option: 1. Participant has Hepatitis B or chronic Hepatitis C Diagnosis 2. Participant has ALT \>=5x ULN 3. Participant has clinical history of liver cirrhosis or current clinical evidence of cirrhosis 4. Previous hypersensitivity reaction to cabotegravir 5. Receiving the following co-administered drugs for which significant decreases in
Interventional (clinical trial)
984
Randomized
Parallel Assignment
CAB-LA will be offered to participants that are initially assigned to the Dynamic Choice Prevention delivery model.
Open label
None (Open Label)
PrEP
HIV
NCT02478463
https://clinicaltrials.gov/study/NCT02478463
Phase I
Completed
ViiV Healthcare
Not provided
Determine the PK concentrations of CAB following LA administration in relevant tissues and fluids of healthy men and women following a single 600 mg IM dose.
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2017-02-27
Anticipated Date of Last Follow-up
2020-06-02
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2019-07-25
Actual Completion Date
2019-07-25
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: - Between 18 and 55 years of age inclusive, at the time of signing the informed consent. - Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. - Body weight >= 40 kilogram (kg) and body mass index (BMI) within the range 18.5 to 35 kg /meter square (inclusive). - Male or female. - Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. - All subjects participating in the study must be counselled on safe sexual practices including the use of effective barrier methods to minimize risk of HIV transmission.
Interventional (clinical trial)
19
Not provided
Single group assignment
Not provided
Open label
None (Open Label)
PrEP
HIV
NCT03422172
https://clinicaltrials.gov/study/NCT03422172
Phase I
Completed
ViiV Healthcare
Not provided
Evaluate the PK, safety, tolerability, and acceptability of CAB LA in adult HIV uninfected Chinese male subjects at low risk for HIV acquisition.
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2018-04-10
Anticipated Date of Last Follow-up
2021-05-12
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2020-04-20
Actual Completion Date
2020-04-20
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: - Subjects must be 18 to 65 years of age inclusive, at the time of signing the informed consent. - Subjects are male at birth. - Subjects who have non-reactive point of care (POC) HIV test and undetectable HIV-1 ribose nucleic acid (RNA) at screening. - At risk of acquiring HIV, defined as having at least one casual male or female sex partner in the past 24 months. - Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring at the time of screening. - Capable of giving written informed consent. - Agree to appropriate use of contraceptive measures during heterosexual intercourse. - Willing to undergo all required study procedures.
Interventional (clinical trial)
48
Not provided
Single group assignment
Eligible subjects will receive oral doses of CAB for 4 weeks followed by IM dosing with CAB LA at Week 5, Week 9, Week 17, Week 25 and Week 33.
Open label
None (Open Label)
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men | https://doi.org/10.1128/aac.02057-21 |
NCT06134362
https://clinicaltrials.gov/study/NCT06134362
Phase III
Active, not recruiting
ViiV Healthcare
The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs (adverse events) leading to withdrawal.
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
Intervention 1
Not provided
Anticipated Start Date
2024-04-01
Actual Start Date
2024-05-14
Anticipated Date of Last Follow-up
2026-11-04
Estimated Primary Completion Date
2029-03-14
Estimated Completion Date
2029-03-14
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Yes
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion criteria: Type of participant 1. Participants must have recently completed or be currently enrolled and ongoing in one of the following studies on the CAB LA arm: * HPTN 083 open label extension * HPTN 084 open label extension (including pregnancy sub-study) Participants that completed study participation ≥3 months ago must be discussed with the Medical Monitor prior to enrolment. Participants who have prematurely withdrawn from prior CAB PrEP studies cannot enroll into this study. 2. Evidence of continued benefit (HIV negative and at risk) from CAB LA during participation in the parent study/sub-study. 3. Participants must have nonreactive HIV tests at Screening (rapid test, immunoassay \[antigen/antibody\] test and HIV-1 RNA results must all be available and no
Interventional (clinical trial)
2998
Not provided
Single group assignment
Not provided
Open label
None (Open Label)
PrEP
HIV
NCT05986084
https://clinicaltrials.gov/study/NCT05986084
Marketed
Active, not recruiting
Beth Israel Deaconess Medical Center
The goal of this this hybrid safety/implementation study is to evaluate whether using long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP) is acceptable, feasible and safe in post-partum people who are breastfeeding. The main question\[s\] it aims to answer are: * Will CAB-LA injections work well as a way to prevent HIV infection in post-partum people? * Will CAB-LA injections be safe in post-partum people and their infants who will be breastfeeding? Participants without HIV who are admitted to the maternity ward after having delivered a baby will be offered to start CAB-LA PrEP. Those who choose to participate will receive their first dose (injection) at the maternity ward and their follow up doses (injections) at their local clinic when they come for routine post-partum and pedi
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-11-30
Anticipated Date of Last Follow-up
2026-07-29
Estimated Primary Completion Date
2027-08-31
Estimated Completion Date
2027-08-31
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Yes
Accepts healthy individuals
No
Inclusion Criteria: 1. Mother 18 years of age or older and willing and able to provide an informed consent 2. \< 14 days after delivery (calendar day of birth = day 0) 3. Negative HIV screening test (conducted at the time of enrollment) 4. Mother \<30 years old or has had \< 3 prior pregnancies (Gravida 1, 2, or 3 including this pregnancy) 5. Plan to stay and receive postpartum and pediatric care in the Gaborone or Molepolole region for 24 months Exclusion Criteria: 1. Receiving carbemazapine, phenobarbital, phenytoin, oxycarbazepine, rifampin, rifabutin, rifapentine, systemic dexamethasone (\>1 dose oral/IV), or St. John's wort 2. Suspected to have, recently diagnosed with, or on treatment for TB (due to interaction with rifampin) 3. Previous hypersensitivity reaction to CAB or other I
Interventional (clinical trial)
500
Not provided
Single group assignment
Not provided
Open label
None (Open Label)
PrEP
HIV
NCT06138600
https://clinicaltrials.gov/study/NCT06138600
Phase III
Suspended
University of Witwatersrand, South Africa
This is a mixed methods study employing a convergence model triangulation design. Participants in the study will be sexually active young adults starting Pre-exposure Prophylaxis at private pharmacies, who will be offered either Cabotegravir Long-Acting Injectable, oral Pre-exposure Prophylaxis (TDF/FTC\[3TC\]), or Pre-exposure Prophylaxis deferment at each of their regular visits, with the option to switch between options for up to 15 months, with a final exit interview following the transition to standard-of-care. The number of study visits will vary, depending on participant Pre-exposure Prophylaxis choices. Those choosing oral Pre-exposure Prophylaxis will be seen 3 monthly from V2 onwards, but those choosing Cabotegravir Long-Acting Injectable will be seen 2 monthly from V2. A maximum
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-11-01
Anticipated Date of Last Follow-up
2024-06-19
Estimated Primary Completion Date
2025-10-31
Estimated Completion Date
2026-01-31
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion criteria: - Each participant must meet all of the following criteria to be enrolled in this study: 1. Adult male or female (≥18 and ≤ 35 years old) 2. Is self-reported sexually active 3. HIV negative at the time of study enrolment (as determined by a rapid blood test for HIV 1) 4. Body weight ≥ 35 kilograms. 5. Creatinine clearance ≥ 60 mL/min. 6. Willingness to sign informed consent.
Not provided
Interventional (clinical trial)
200
Non-randomized
Parallel Assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT05072093
https://clinicaltrials.gov/study/NCT05072093
Marketed
Completed
Emory University
The study is a prospective cohort of young MSM who are followed for 2 years either in-person at the PRISM Health Research Clinic and/or virtually with telehealth study visits. Follow-up visits occur as frequently as every 3 months, or as appropriate to clinical needs of HIV PrEP or STI PEP. The investigators will enroll men who may decide to start or stop PrEP, change from daily oral PrEP to on-demand oral PrEP or from on-demand oral PrEP to daily PrEP, to start or stop STI PEP at any point in the study period, or injectable PrEP as an alternative to daily oral PrEP or on-demand oral PrEP. All men will be provided with the study's mobile smart phone app to support early identification of risks for PrEP discontinuation, to provide information about STI PEP and document usage patterns of on-
Parrying the Pitfalls of PrEP: Project PEACH
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2021-11-20 00:00:00
Anticipated Date of Last Follow-up
2025-05-29 00:00:00
Estimated Primary Completion Date
2025-02-01 00:00:00
Estimated Completion Date
2025-02-01 00:00:00
Actual Primary Completion Date
2025-03-31 00:00:00
Actual Completion Date
2025-03-31 00:00:00
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * Male at birth * Self-identify as Cisgender Male * Ages 18-45 years * ≥1 male anal sex partner in the 12 months before the baseline interview * Live in the Atlanta MSA * Owns cell phone with data service * Willing to download a health-related app to their cell phone as part of the research study * Able to provide ≥ 2 means of contact * Not currently enrolled in another HIV prevention clinical trial * Confirmed HIV-negative at baseline visit Exclusion Criteria: * Female at birth * Do not self-identify as Cisgender Male * Individuals \< 18 years of age or \> 45 years of age * HIV positive status * No male anal sex partner in the 12 months before the baseline interview * Does not own mobile phone with data service * Not willing to download a health-related app to their
Interventional (clinical trial)
240
Not provided
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06133686
https://clinicaltrials.gov/study/NCT06133686
Phase III
Not yet recruiting
MRC/UVRI and LSHTM Uganda Research Unit
Title: Implementing oral (event-driven and daily) and long-acting Pre-exposure prophylaxis (PrEP) in mobile men in Sub-Saharan Africa Design: A mixed method, multi-setting, multi-country, phase 3b, open-label, hybrid type 2 implementation and effectiveness randomized controlled trial (RCT). The trial will be carried out in 400 HIV negative men aged 18+ years in South Africa and Uganda. Men will be randomized 1:1 to either Group A: oral Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) PrEP (event-driven or daily) or Group B: Long-acting injectable cabotegravir (CAB-LA) over 9-months. After 9-months participants from both groups will be offered choice of PrEP (oral TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Various strategies to support Pr
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa
Intervention 1
Intervention 2
Not provided
Not provided
Anticipated Start Date
2024-04-01
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2023-11-13
Estimated Primary Completion Date
2025-12-31
Estimated Completion Date
2027-04-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: 1. Able and willing to provide informed consent 2. Aged 18 years and above on the day of screening 3. Willing to have a HIV test and receive the test results 4. Male at birth 5. In the past 6-months has travelled for work or to find work and spent at least one night away from home for work related purposes. 6. Available for follow up for the duration of the study Exclusion Criteria: 1. Known HIV infection 2. Confirmed HIV-positive test result, indeterminate HIV test result, and/or signs and symptoms of an acute HIV infection 3. Body weight less than 35Kg at baseline 4. Allergy to any of the study products 5. Medical, social or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or safety of the participant (e.g
Interventional (clinical trial)
400
Randomized
Parallel Assignment
Not provided
Open label
Not provided
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Project website | https://www.kcl.ac.uk/research/mobile-men | |
| Link | Mobilemen project website | https://www.kcl.ac.uk/research/mobile-men | |
| Link | Mobile men newsletter July 2025 | https://www.kcl.ac.uk/assets/lsm/pdf/mobile-men-newsletter-july-2025.pdf | |
| Link | Mobile Men newsletter Oct 2024 | https://www.kcl.ac.uk/assets/research/project-upload-2021/mobile-men-newsletter-oct-2024.pdf | |
| Link | Mobile Men Newsletter May 2024 | https://www.kcl.ac.uk/assets/research/project-upload-2021/mobile-men-newsletter-may-2024.pdf | |
| Link | Mobile Men Newsletter October 2023 | https://www.kcl.ac.uk/assets/research/project-upload-2021/mobile-men-newsletter-october-2023.pdf |
NCT06319105
https://clinicaltrials.gov/study/NCT06319105
Marketed
Active, not recruiting
Georgetown University
The purpose of this study is to evaluate the implementation and clinical outcomes of expanded pre-exposure prophylaxis delivery modalities and service delivery points offering long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high-priority groups through diverse delivery channels.
PathToScale: An Implementation Evaluation
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2024-03-26
Anticipated Date of Last Follow-up
2024-03-28
Estimated Primary Completion Date
2026-04-01
Estimated Completion Date
2026-04-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
older than 15yo
Observational studies (incl. patient registries)
9900
Non-randomized
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT05867212
https://clinicaltrials.gov/study/NCT05867212
Marketed
Completed
Kelley-Ross & Associates, Inc.
The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting. The main question it aims to answer are: * Is the program feasible and acceptable at the end of 1 year of operations? * What are the facilitators and barriers of the program? Participants who want to start the FDA approved cabotegravir long acting injectable medication for PrEP will have the option participating in surveys and a review of their electronic health records. Medication will be administered based on FDA approved labeling guidelines and their PrEP care will be part of standard of care per CDC. Pharmacists who want to provide the service to their patients will
Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
Intervention 1
Not provided
Anticipated Start Date
2023-06-01
Actual Start Date
2023-05-13
Anticipated Date of Last Follow-up
2025-07-25
Estimated Primary Completion Date
2025-11-30
Estimated Completion Date
2025-11-30
Actual Primary Completion Date
2025-04-30
Actual Completion Date
2025-04-30
Age Cohort
Genders
Accepts pregnant individuals
Yes
Accepts lactating individuals
Yes
Accepts healthy individuals
Yes
Not provided
Observational studies (incl. patient registries)
50
Non-randomized
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06474364
https://clinicaltrials.gov/study/NCT06474364
Marketed
Recruiting
MU-JHU CARE
Several studies show that Adolescents and Young Adults (AYA) have poor outcomes along the entire Human Immunodeficiency Virus (HIV) prevention and care cascades compared to adults. The investigators propose to evaluate novel evidence-based HIV prevention and care interventions (including Cabotegravir LongActing (CABLA) to determine implementation outcomes among AYA who are at particularly high risk for HIV acquisition and poor viral suppression in five geographically distinct research performance sites in Uganda. The results will provide important evidence to inform Uganda and other regional countries' policy on integrated HIV prevention, care and treatment for AYA at high risk for HIV and Sexually Transmitted Infections (STIs) in order to reach the UNAIDS 95-95-95 targets and HIV epidemic
HIV Prevention and Care Interventions for Youth in Uganda
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
2024-07-15
Actual Start Date
2024-08-05
Anticipated Date of Last Follow-up
2025-07-25
Estimated Primary Completion Date
2028-08-31
Estimated Completion Date
2028-08-31
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: Adolescents and young adults with increased likelihood of HIV acquisition * AYA 15 to 24 years of age * Classified as high risk using our screening tool. * Documented HIV un-infected as per the national HIV testing algorithm. * Willing to use PrEP * Willing to provide written informed consent. * No plans to relocate permanently in the next 6 months * No suspicion of acute HIV infection: * Hepatitis B virus surface antigen (HBsAg)-negative and accepts HB vaccination * Having no medical or social condition that, in the opinion of the study investigator, would interfere with the conduct of the study or interpretation of study results. * HIV-uninfected, based on HIV test results obtained at screening and enrolment visit and just prior to randomization. All HIV test res
Interventional (clinical trial)
600
Randomized
Parallel Assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT05937698
https://clinicaltrials.gov/study/NCT05937698
Marketed
Terminated
FHI 360
The CATALYST study is an implementation study that will characterize and assess the implementation of an enhanced service delivery package providing informed choice of pre-exposure prophylaxis (PrEP) products among women at PEPFAR sites in Kenya, Lesotho, South Africa, Uganda, and Zimbabwe.
The CATALYST Study
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-05-30
Anticipated Date of Last Follow-up
2025-03-12
Estimated Primary Completion Date
2025-06-30
Estimated Completion Date
2025-06-30
Actual Primary Completion Date
2025-01-27
Actual Completion Date
2025-01-27
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Observational studies (incl. patient registries)
6069
Non-randomized
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06250504
https://clinicaltrials.gov/study/NCT06250504
Phase III
Recruiting
Africa Health Research Institute
The goal of this hybrid (1a) Cluster Randomised Controlled Trial phase 3B trial is to evaluate the effectiveness and implementation of offering a choice of HIV Pre-Exposure Products (PrEP) through community-based sexual and reproductive health services, on PrEP uptake and retention, and population prevalence of sexually transmissible HIV amongst adolescents and young adults living in rural South Africa. Researchers will compare adding the choice of long-acting PrEP, i.e. two monthly injectable cabotegravir (CAB LA) or dapiravine vaginal ring and HIV post exposure prophylaxis packs to daily oral PrEP integrated with community-based SRH in the 20 intervention clusters with standard of care (SoC), daily oral PrEP integrated with community-based SRH in the 20 control clusters, on uptake and r
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2024-02-27
Anticipated Date of Last Follow-up
2026-07-07
Estimated Primary Completion Date
2025-07-01
Estimated Completion Date
2026-10-01
Actual Primary Completion Date
2026-04-30
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: All young men and women aged 15-30 who are residing in the 40 administrative clusters in the study district and attend any integrated SRH/HIV service Documented HIV negative test Suitable for PrEP and/or already on PrEP Weight \> 35 kg Understand the required dosing schedule and HIV testing. Aware that details can be shared with a peer navigator to support their follow-up If pregnant or breast feeding and/or planning to become pregnant participant can be offered CAB LA, if risk of acquiring HIV out weighs unknown risk of CAB LA, but must understand that safety in pregnancy or breast feeding for CAB LA has not been established and oral daily PrEP is a safe alternative. Exclusion Criteria: History or presence of allergy to the study drugs or their components Inv
Not provided
Interventional (clinical trial)
2052
Randomized
Parallel Assignment
Not provided
Double-blind masking
Not provided
Prevention, PrEP
HIV
NCT05799339
https://clinicaltrials.gov/study/NCT05799339
Marketed
Completed
Alexis Roth
The goal of this study is to elicit information crucial for designing strategies to support engagement in cabotegravir, a long-acting injectable form of pre-exposure prophylaxis (PrEP) to reduce HIV risk among women who inject drugs (WWID), a population with high unmet need that has been understudied in all phases of PrEP research. The main questions this study aims to answer are: 1. How do WWID perceive long-acting injectable cabotegravir (CAB-LA) as a HIV prevention tool? 2. If and how their decisions to initiate CAB-LA as PrEP are informed by their experiences with other long-acting medications, experience with daily oral medications, and their personal circumstance (e.g., like housing or addition severity)? 3. Do PrEP outcomes (e.g., adherence) and engagement in care over time differ
Optimizing CAB-LA as PrEP for Women Who Inject Drugs
Not provided
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2022-01-13
Anticipated Date of Last Follow-up
2025-12-20
Estimated Primary Completion Date
2025-12-30
Estimated Completion Date
2025-12-30
Actual Primary Completion Date
2025-07-31
Actual Completion Date
2025-07-31
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Women who inject drugs
Observational studies (incl. patient registries)
144
Non-randomized
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06970223
https://clinicaltrials.gov/study/NCT06970223
Phase I
Active, not recruiting
ViiV Healthcare
This study will evaluate the tolerability and acceptability of injection site reactions (ISRs) of two long-acting (LA) injectables. Additional characteristics of the ISRs will be investigated and described as well as safety outcomes.
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2025-04-22
Anticipated Date of Last Follow-up
2025-11-21
Estimated Primary Completion Date
2025-07-30
Estimated Completion Date
2026-07-10
Actual Primary Completion Date
2025-07-15
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Yes
Accepts lactating individuals
Yes
Accepts healthy individuals
Yes
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. At the time of obtaining informed consent, 18 years of age. 2. Body weight 50 kg and BMI within the range 18 to 32 kg/m2 (inclusive). 3. Participants who are overtly healthy as determined by medical evaluation by a responsible and experienced physician, including medical history, physical examination, laboratory tests and cardiac monitoring. 4. A participant with a significant clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included if the investigator determines and documents that the finding is unlikely to introduce additional
Interventional (clinical trial)
65
Randomized
Cross-over assignment
Not provided
Open label
Not provided
Not provided
Not provided
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Publication | Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals | K. Brown ; EACS2025; Moderated ePoster; October 17 2025 ;MeP20.4.LB | |
| Publication | J. Boles, et al. Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals. Presented at the European AIDS Conference (EACS 2025), 15-18 October, Paris, FR. | Presented at the European AIDS Conference (EACS 2025), 15-18 October, Paris, FR. |
NCT04824131
https://clinicaltrials.gov/study/NCT04824131
Phase II
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2020-11-04
Anticipated Date of Last Follow-up
2024-11-07
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2023-01-10
Actual Completion Date
2023-01-10
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * Assigned female at birth * At enrollment, below 18 years of age * At enrollment, body weight ≥ 35 kg (77 lbs.) * Willing and able to provide informed assent/consent for the study and/or able to obtain written parental/guardian informed consent * Self-reported sexual activity with a male (oral, anal or vaginal) in the past 12 months * Willing and able to undergo all study procedures * In general, good health, as evidenced by the following laboratory values: * Non-reactive / negative HIV test results\*\*, * Absolute neutrophil count \> 799 cells/mm3, * Platelet count ≥ 100,000/mm3, * Hemoglobin ≥ 11g/dL, * Calculated creatinine clearance ≥ 60 mL/minute using the modified Schwartz equation, * Alanine aminotransferase (ALT) \< 2.0 times the upper limit of no
Interventional (clinical trial)
55
Not provided
Single group assignment
Not provided
Open label
Not provided
Not provided
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | In the Face of a Global Pandemic and Social Barriers, Cisgender Female Adolescents Enroll in HIV Prevention Trial HPTN 084-01 in Sub-Saharan Africa | https://www.hptn.org/sites/default/files/inline-files/HPTN%20084-01_Abstract-oral%20pres-09SEPT2021-FINALV1.0.pdf | |
| Link | HPTN 084-01 website with key publications ! | https://www.hptn.org/research/studies/hptn-084-01 |
NCT06807736
https://clinicaltrials.gov/study/NCT06807736
Marketed
Recruiting
Desmond Tutu HIV Foundation
The goal of this clinical trial is to offer adolescents and young people in Cape Town, South Africa different HIV pre-exposure prophylaxis (PrEP) products and describe how they use these products over an 18-month period. The study has both clinical and implementation primary aims. The primary clinical aim is short and long-term persistence on PrEP. Persistence is defined as the length of time that a participant shows continuous use of a PrEP product as intended, without stopping PrEP or switching to another PrEP product. The primary implementation aim involves the determination of factors that either enable or serve as a barrier to PrEP uptake and continuation. Participants will be offered a choice between three antiretroviral-containing PrEP products: (1) a Tenofovir-based oral tablet th
PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offere
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2024-02-13
Anticipated Date of Last Follow-up
2025-01-29
Estimated Primary Completion Date
2025-12-31
Estimated Completion Date
2026-03-31
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Not provided
1800
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
NCT06273943
https://clinicaltrials.gov/study/NCT06273943
Phase III
Active, not recruiting
ANRS, Emerging Infectious Diseases
The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
2024-04-01
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2024-02-21
Estimated Primary Completion Date
2025-10-30
Estimated Completion Date
2026-10-30
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Inclusion criteria * Age ≥ 18 years. * Cisgender men who have sex with men. * Have taken oral TDF/FTC based PrEP during the past 6 months, either daily or on-demand, with a documented PrEP prescription. * Agreeing to be contacted personally by telephone (call, SMS) or e-mail. * Person affiliated with or a beneficiary of a social security scheme (article L1121-11 of the Public Health Code). * Informed and written consent, signed by the person and the investigator on the day of inclusion, at the latest, and before any examination carried out within the setting of the study (article L1122-1-1 of the Public Health Code). Non-inclusion criteria * Positive HIV test result at screening or enrollment visit, even if HIV infection is not confirmed. * Symptoms and/or clinical signs consistent with
Not provided
Interventional (clinical trial)
322
Randomized
Parallel Assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06145854
https://clinicaltrials.gov/study/NCT06145854
Marketed
Active, not recruiting
Midway Specialty Care Center
Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2024-01-02
Anticipated Date of Last Follow-up
2025-10-30
Estimated Primary Completion Date
2026-10-30
Estimated Completion Date
2027-03-31
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Unspecified
Genders
Unspecified
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Not provided
Not provided
100
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
NCT05949203
https://clinicaltrials.gov/study/NCT05949203
Marketed
Active, not recruiting
Oregon Health and Science University
This demonstration study will evaluate the real-world implementation of long-acting cabotegravir (CAB-LA) for HIV pre-exposure prevention (PrEP) through a partnership between the OHSU Tele-PrEP Program (TPP) and the OHSU Home Infusion Pharmacy (HIP). The study will perform a formative evaluation of the TPP/HIP partnership to determine its merit and worth, with revisions made as needed to improve the program, which is reflective of a real-world program rollout. The study is observational, and there is no comparison group. The primary objective is to evaluate adherence to CAB-LA by both urban and rural participants using the TPP/HIP partnership. The goals of the study are improve the TPP/HIP program itself with attention to reducing geographic disparities, and to disseminate best practices a
Oregon PrEP at Home Study
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-12-01
Anticipated Date of Last Follow-up
2023-12-05
Estimated Primary Completion Date
2025-12-01
Estimated Completion Date
2025-12-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Unspecified
Genders
Unspecified
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Not provided
Not provided
125
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
NCT06868641
https://clinicaltrials.gov/study/NCT06868641
Marketed
Recruiting
Columbia University
The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention: for participants discontinuing cab-LA, this will consist of monthly cabotegravir drug level monitoring to provide personalized HIV prevention coaching, for participants considering discontinuing cab-LA or LEN, this will consist of a one-time personalized HIV prevention coaching session. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study.
The TAIL-PrEP Study
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
2026-01-01
Actual Start Date
2026-06-03
Anticipated Date of Last Follow-up
2026-09-16
Estimated Primary Completion Date
2026-12-01
Estimated Completion Date
2027-03-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion criteria: * At least 18 years of age * HIV-negative (self-report) * Able to speak and read in English * Have access to an internet-connected device capable of running the online video conferencing platform * Have a private location at which to take online conference calls Participants considering discontinuing cab-LA or LEN have the following additional inclusion criteria: \- Considering discontinuing cab-LA or LEN Participants discontinuing cab-LA have the following additional inclusion criteria: * Have discontinued cab-LA injections within the last three months * Not currently on cab-LA injections * Able to receive and send monthly packages * The study period will end for patient participants once the monthly blood draw result indicates that cab-LA levels are not detectabl
Not provided
Interventional (clinical trial)
30
Not provided
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06854029
https://clinicaltrials.gov/study/NCT06854029
Marketed
Not yet recruiting
Duke University
The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
2026-12-01
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2026-11-04
Estimated Primary Completion Date
2029-12-01
Estimated Completion Date
2030-06-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: 1. Adults (age 18) at a participating carceral site; 2. Eligible for release within 120 days (sentenced and/or pretrial). Individuals who might be sentenced to federal prison will be excluded; 3. History of OUD (meeting DSM-5 criteria of moderate or severe opioid use disorder at the time of incarceration; individuals not meeting the opioid-disorder criterion will be eligible if they were treated in an opioid agonist treatment program during the year before incarceration or met OUD criteria in the year prior to incarceration); 4. HIV negative (as confirmed by a HIV rapid test); 5. Clinically indicated for PrEP based on CDC guidelines during incarceration and/or the year prior to incarceration; 6. Willing to enroll in buprenorphine treatment and PrEP and be randomized to
Not provided
Interventional (clinical trial)
450
Not provided
Parallel Assignment
Not provided
Single blind masking
Not provided
PrEP
HIV
NCT06834113
https://clinicaltrials.gov/study/NCT06834113
Marketed
Recruiting
Centre Hospitalier Régional d'Orléans
This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®) in patients infected with HIV-1, depending on the injection site and whether or not they are wearing a virtual reality headset. The reference group being the dorsogluteal injection without headset. Participants who meet the study criteria will be randomized into 1 of 24 sequences. A sequence is composed by 4 injections procedures: dorsogluteal intramuscular injection (A), ventrogluteal intramuscular injection (B), dorsogluteal intramuscular injection with virtual reality headset (C), ventrogluteal intramuscular injection with virtual reality headset (D). Each pa
Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2025-01-24
Anticipated Date of Last Follow-up
2025-05-28
Estimated Primary Completion Date
2026-07-24
Estimated Completion Date
2026-09-24
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Inclusion Criteria: * Patient aged at least 18 years; * Patient infected with HIV-1; * Patient virologically controlled (VL \< 50 copies/ml); * Patient scheduled to receive treatment with cabotegravir and rilpivirine (naïve patients) or currently on injectable cabotegravir and rilpivirine, prescribed by their referring physician. Exclusion Criteria: * Patient(s) on another injectable antiretroviral treatment; * Patient participating in another clinical trial with medication; * Patient(s) with epilepsy; * Patient on antidepressant treatment; * Patient(s) with psychiatric or behavioral disorders; * Patient(s) with a history of dizziness and motion sickness that prevents the use of virtual reality headset; * Patient(s) with visual and hearing impairments that prevent the use of virtual rea
Not provided
Interventional (clinical trial)
120
Randomized
Cross-over assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT07199335
https://clinicaltrials.gov/study/NCT07199335
Marketed
Recruiting
Massachusetts General Hospital
The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
Intervention 1
Not provided
Anticipated Start Date
2025-11-01
Actual Start Date
2026-02-24
Anticipated Date of Last Follow-up
2026-03-17
Estimated Primary Completion Date
2028-12-01
Estimated Completion Date
2028-12-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
No
Other(s): People who inject drugs Inclusion Criteria: * HIV Ab/Ag test (lab-based or rapid) negative at time of enrollment * ≥18 years old * Able to provide informed consent * Have injected non-prescribed drugs within the past 6 months * No prior history of receiving cabotegravir (Note: prior or active use of non-CAB PrEP (\[FTC/TDF or FTC/TAF\]) at screening is allowed, but participant will need to indicate that they prefer to switch to injectable PrEP). * PrEP provider deems cabotegravir use to be appropriate per the applicable prescribing information prior to enrollment in the study. Exclusion Criteria: * Pregnant or breastfeeding people. Should a participant become pregnant, the treating physician will discuss with the participant whether to continue study medication, taking into consideration the risks and benefits
Interventional (clinical trial)
100
Not provided
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT05746065
https://clinicaltrials.gov/study/NCT05746065
Marketed
Completed
University of Washington
INSIGHT is a Prospective, Observational, open-label cohort study on women in Sub-Saharan Africa on PrEP screening, informed choice, and compliance. There are no specific intervention arms or comparative treatment plans. We will follow and observe participants taking PrEP, not taking PrEP, as well as those who begin or end PrEP during the course of the observational period. This project will offer a PrEP delivery package within a prospective cohort study of sexually active HIV negative women ages 16-30 in locations in eSwatini, Kenya, Malawi, South Africa, Uganda, Zambia, and Zimbabwe to understand PrEP uptake, use, persistence and preferences for attributes of long-acting PrEP products and aspects of PrEP delivery for long-acting PrEP
A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2022-08-01
Anticipated Date of Last Follow-up
2024-05-06
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2023-08-01
Actual Completion Date
2023-08-01
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
16-30 yo females
Observational studies (incl. patient registries)
3087
Non-randomized
Not provided
Not provided
Open label
Not provided
Prevention, PrEP
HIV
NCT07275606
https://clinicaltrials.gov/study/NCT07275606
Phase I/II
Recruiting
ViiV Healthcare
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
2026-03-17
Actual Start Date
2026-04-15
Anticipated Date of Last Follow-up
2026-05-15
Estimated Primary Completion Date
2029-10-10
Estimated Completion Date
2029-10-10
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * At least 37 weeks gestation at delivery. * \<=10 days of life. * Birth weight at least 2 kg. * At Entry, neonate has initiated standard of care Antiretroviral drug (ARV) prophylaxis. * At Entry, neonate is generally healthy as determined by the site Investigator based on review of all available medical history information and physical examination findings. * Mother is on a Dolutegravir (DTG) based regimen for a minimum of 4 weeks prior to delivery, regardless of maternal viral load. * Mother is currently breastfeeding or plans to breastfeed infant. * Mother is of legal age or circumstance to provide independent informed consent and is willing and able to provide documented informed consent for her and her infant's participation in this study. * Mother has confirmed H
Not provided
Interventional (clinical trial)
44
Not provided
Sequential assignment
Not provided
Open label
Not provided
Not provided
Prevention, PrEP, Prevention of vertical transmission (PVT), Infant post-exposure prophylaxis
HIV
NCT07516548
https://clinicaltrials.gov/study/NCT07516548
Marketed
Recruiting
University of Alabama at Birmingham
This study is being done to understand how long-acting injectable cabotegravir (CAB-LA) used for HIV pre-exposure prophylaxis (PrEP) and hormonal contraceptive methods affect each other when used at the same time. Women who are already using CAB-LA or not using PrEP will choose to join one of several groups based on whether they use injectable contraceptive (IM DMPA), an etonogestrel implant, or no hormonal contraceptive. Participants will have study visits every 4 to 12 weeks for up to 12 or 24 weeks after starting a contraceptive method to collect blood samples and measure levels of CAB-LA and hormone concentrations. The study will compare these levels to see if taking CAB-LA changes hormone concentrations or if using hormonal contraception changes CAB-LA drug levels. Safety, side effect
Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIV
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
2026-08-01
Actual Start Date
2025-01-24
Anticipated Date of Last Follow-up
2026-10-12
Estimated Primary Completion Date
2026-12-01
Estimated Completion Date
2026-12-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Yes
Accepts healthy individuals
Yes
Not provided
Observational studies (incl. patient registries)
105
Non-randomized
Not provided
Not provided
Open label
Not provided
PrEP
HIV
NCT01754116
https://clinicaltrials.gov/study/NCT01754116
Phase I
Completed
ViiV Healthcare
This is a single-center, randomized, open-label, 3 parallel treatment study in healthy adult subjects to assess the relative bioavailability of new formulations of GSK1265744 LAP 400 mg intra muscular compared to the current GSK1265744 LAP 400 mg nanomilled formulation. This study will evaluate LAP formulations of GSK1265744 with different particle sizes. Following a 14 day lead in period with oral GSK1265744, forty-five subjects will receive 400 mg of one of three GSK1265744 formulations which vary in particle size from 200 nm to 5 um by intramuscular injection. Samples for determination of GSK1265744 concentrations will be collected for 12 weeks post-injection. Safety will be evaluated by adverse event recording and laboratory values at frequent intervals throughout the trial. A subgrou
A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2013-01-01
Anticipated Date of Last Follow-up
2014-04-17
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2014-04-01
Actual Completion Date
2014-04-01
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria * Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent. * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * A female subject is eligible to participate if she is of: non-childbearing potential. Female subjects of child bearing potential must agree to use contraception for at least 6 months after the final dose of study drug and should understand that drug concentrations may be measurable for up to one year after final dose. * Male subjects with female partners of child-bearing potential must agree to use one of the required contraception methods noted in the protocol. * Body weight \>=50
Not provided
Interventional (clinical trial)
43
Randomized
Parallel Assignment
Not provided
Open label
Not provided
Not provided
PrEP
HIV
NCT01756131
https://clinicaltrials.gov/study/NCT01756131
Phase I
Completed
ViiV Healthcare
A single dose escalation study to determine the safety, tolerability, and pharmacokinetic profile of intramuscular and subcutaneous injections of GSK1265744 long acting parenteral (LAP) in healthy subjects. This study consists of a screening visit, a single injection, and follow-up evaluations for a minimum of 12 weeks following the injection.
A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Intervention 1
Intervention 2
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2010-09-01
Anticipated Date of Last Follow-up
2013-05-16
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2012-12-01
Actual Completion Date
2012-12-01
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. * Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent. * Females of childbearing potential with a negative pregnancy test (serum or urine) at screen and at Day -1, and agrees to use one of the contraception methods listed in th
Not provided
Interventional (clinical trial)
72
Randomized
Single group assignment
Not provided
Single blind masking
Not provided
Not provided
Not provided
HIV
NCT07390409
https://clinicaltrials.gov/study/NCT07390409
Marketed
Not yet recruiting
Desmond Tutu HIV Foundation
The ALIGN study will evaluate the delivery of injectable Lenacapavir (LEN), a long-acting injectable formulation for HIV pre-exposure prophylaxis (PrEP), amongst adolescents and young people (aged 15-35 years) living within the Klipfontein-Mitchell's health sub-district of Cape Town, South Africa. LEN will be offered alongside injectable Cabotegravir long-acting (CAB LA), an injectable PrEP product already approved for use in South Africa, and oral PrEP (F/TDF) modalities (including intermittent dosing where appropriate), the current standard of care (SOC) biomedical HIV prevention in South Africa. Following counselling, participants will be able to choose which PrEP product (LEN, CAB LA, or oral PrEP) to initiate, with the option to switch at any future clinical visit, and followed for 18
ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
2026-01-29
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2026-01-29
Estimated Primary Completion Date
2028-03-01
Estimated Completion Date
2028-05-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
All participants must be HIV negative at baseline. 15-35 years All participants must have a body weight ¬> 35kg at baseline
Not provided
3700
Non-randomized
Not provided
Not provided
Open label
Not provided
PrEP
HIV
NCT06786520
https://clinicaltrials.gov/study/NCT06786520
Phase I
Active, not recruiting
ViiV Healthcare
This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2025-01-17
Anticipated Date of Last Follow-up
2026-11-04
Estimated Primary Completion Date
2027-03-08
Estimated Completion Date
2027-03-08
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * Adult participants greater than or equal to (\>=) 18 years old, weighing at least 35 kg. * Participants who are overtly healthy as determined by medical evaluation. * Assigned male sex at birth or assigned female sex at birth. Participants assigned female sex at birth are eligible to participate if they are of non-childbearing potential, or if they are of childbearing potential and are not pregnant (confirmed by test), not breastfeeding, and are using a highly effective contraceptive method. * Capable of giving written informed consent. Healthcare staff will be eligible for inclusion in this study if: * They are site employees responsible for administrative or clinical aspects of offering and administering CAB under the protocol at the site. * Has the required qual
Interventional (clinical trial)
69
Not provided
Single group assignment
Participants will receive the CAB LA Q2M regimen up to Month 9 then will receive the CAB ULA Q4M regimen up to Month 23. Key end points are plasma concentration of CAB at the end of the CAB LA 2M phase compared to plasma concentration of CAB at the end of the CAB Q4M phase
Open label
None (Open Label)
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | New formulation of cabotegravir for HIV treatment can be dosed at intervals of at least 4 months | https://www.eatg.org/hiv-news/new-formulation-of-cabotegravir-for-hiv-treatment-can-be-dosed-at-intervals-of-at-least-4-months/ |
NCT04692077
https://clinicaltrials.gov/study/NCT04692077
Phase II
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV prevention for young people.
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2020-02-19
Anticipated Date of Last Follow-up
2025-05-16
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2023-07-07
Actual Completion Date
2023-07-07
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: * Assigned male at birth (includes MSM, TGW, and gender non-conforming people) * At enrollment, aged below 18 years * At enrollment, body weight ≥ 35 kg (77 lbs.) * Willing to provide informed consent for the study * Self-reported sexual activity with a male in the past 12 months * In general, good health, as evidenced by the following laboratory values * Non-reactive/negative HIV test results * Absolute neutrophil count \> 799 cells/mm3 * Platelet count ≥ 100,000 cells/mm3 * Hemoglobin ≥ 11g/dL * Calculated creatinine clearance ≥ 60 mL/minute using modified Schwartz equation (≤ grade 2) * Alanine aminotransferase (ALT) \< 2.0 times the upper limit of normal (ULN) and total bilirubin (Tbili) ≤ 2.5 x ULN * Hepatitis B virus (HBV) surface antigen (HBsAg) n
Interventional (clinical trial)
9
Not provided
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT06158126
https://clinicaltrials.gov/study/NCT06158126
Marketed
Recruiting
University of North Carolina, Chapel Hill
The primary purpose of this study is to assess the safety of long-acting injectable cabotegravir (CAB-LA) and oral pre-expose prophylaxis (PrEP) (FTC/TDF or 3TC/TDF) for the prevention of HIV during pregnancy and breastfeeding among pregnant women and their infants in Malawi. The main question the study aims to answer is: \- Do composite adverse pregnancy events, maternal health outcomes, and/or infant health outcomes differ between individuals taking oral PrEP and those taking CAB-LA? Women who are already using PrEP at the time of pregnancy diagnosis or those who initiate PrEP during pregnancy will enroll into a Safety Cohort where they will be closely followed up during pregnancy while optimizing their antenatal care (ANC) per the Malawi ANC package. Women will have access to either C
UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2024-04-17
Anticipated Date of Last Follow-up
2026-05-01
Estimated Primary Completion Date
2026-12-01
Estimated Completion Date
2027-12-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Yes
Accepts lactating individuals
Yes
Accepts healthy individuals
Yes
Inclusion Criteria: Maternal participants: * Confirmed pregnancy by urine pregnancy test or ultrasound. * Aged 15 years or older * PrEP-eligible by Malawi local guidelines * Confirmed HIV-negative based on the local HIV testing algorithm * Hepatitis B surface antigen (HBsAg) negative * Weight \>35 kg * Provided informed consent and expressed willingness to participate in study activities with their infants. Infant participants: Infant participants will enter the study with their mother as unborn infants. There are no specific eligibility criteria for infant participation otherwise. Exclusion Criteria: Maternal participants will not be eligible to enter the prospective cohort study if any of the following conditions are identified during the screening process: * Known to be living wit
Interventional (clinical trial)
621
Not provided
Parallel Assignment
Not provided
Open label
Not provided
Prevention, PrEP, Prevention of vertical transmission (PVT), Infant post-exposure prophylaxis
HIV
NCT06741397
https://clinicaltrials.gov/study/NCT06741397
Phase II
Active, not recruiting
ViiV Healthcare
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2024-12-20
Anticipated Date of Last Follow-up
2026-09-29
Estimated Primary Completion Date
2026-09-09
Estimated Completion Date
2029-08-30
Actual Primary Completion Date
2026-09-09
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Inclusion Criteria: 1. At the time of obtaining informed consent, adolescent and adult participants weighing at least 35 kg. 2. Participants must have a nonreactive HIV test at Screening (rapid test, nonrapid HIV immunoassay, and HIV RNA) and enrollment (a rapid test, nonrapid HIV immunoassay, and HIV RNA). 3. Participants who are at risk of acquiring HIV, defined as having had anal or vaginal sex in the past 6 months. 4. Participants who are overtly healthy as determined by medical evaluation by a responsible and experienced physician, including medical history, physical examination, laboratory tests and cardiac monitoring at the time of screening. 5. No alcohol or substance use that, in the opinion of the study investigator and medical monitor, would interfere with the conduct of the st
Interventional (clinical trial)
229
Randomized
Single group assignment
Key end point: CAB trough concentrations Participants receive lead-in injections comprising cabotegravir LA during month one and injections of a new formulation of CAB LA at Month 3, Month 5 and every 4 months thereafter to Month 29
Open label
This is an open label study.
PrEP
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | New formulation of cabotegravir for HIV treatment can be dosed at intervals of at least 4 months | https://www.eatg.org/hiv-news/new-formulation-of-cabotegravir-for-hiv-treatment-can-be-dosed-at-intervals-of-at-least-4-months/ | |
| Link | Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment | https://www.aidsmap.com/news/mar-2024/ultra-long-acting-cabotegravir-could-be-taken-three-times-year-hiv-prep-and-treatment | |
| Document | Baseline Demographics in the Phase 2b Registrational EXTEND 4M Trial: Evaluating a Novel Every-4-Month Cabotegravir Formulation in a Population Who Could Benefit From PrEP | 000025 EXTEND 4M BL Demographics.pdf | Y7sXJELLTepy_000025-extend-4m-bl-demographics.pdf |
| Link | Baseline Demographics in the Phase 2b Registrational EXTEND 4M Trial: Evaluating a Novel Every-4-Month Cabotegravir Formulation in a Population Who Could Benefit From PrEP | https://www.natap.org/2026/IAS/IAS_36.htm |
NCT07672717
https://clinicaltrials.gov/study/NCT07672717
Phase I
Recruiting
Johns Hopkins University
This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.
Cabotegravir-Hormone PK/PD Interactions for HIV Prevention
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2026-07-07
Anticipated Date of Last Follow-up
2026-07-10
Estimated Primary Completion Date
2030-12-01
Estimated Completion Date
2031-12-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: * 19 years of age or older * For persons using exogenous hormones, must be on a stable regimen for ≥6 months and remain on that regimen throughout study conduct, and exogenous hormone regimens must be prescribed and managed under the care of a healthcare professional * For females, must be on a non-hormonal contraceptive agent, and must persist in contraceptive use for the duration of the study * Body weight greater than 35 kg (77.2 lbs) * HIV-1 uninfected at screening and enrollment as documented by an instrumented Ag/Ab assay and HIV-1 RNA testing * Understand and agree to local STI reporting requirements * Willing to abstain from additional antiretroviral agents (including PrEP agents, F/TAF and F/TDF) during the duration of the study * Willing to abstain from inser
Not provided
Interventional (clinical trial)
32
Not provided
Single group assignment
Not provided
Open label
Not provided
PrEP
HIV
NCT07473778
https://clinicaltrials.gov/study/NCT07473778
Not provided
Recruiting
Gilead Sciences
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine clinical practice when LEN is added as PrEP option and will evaluate persistence on LEN PrEP. The primary objective of this study is to evaluate real-life persistence on LEN PrEP at Week 52 in diverse clinical settings in the United States.
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2026-03-17
Anticipated Date of Last Follow-up
2026-10-19
Estimated Primary Completion Date
2028-04-01
Estimated Completion Date
2029-04-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Observational studies (incl. patient registries)
3000
Non-randomized
Not provided
Not provided
Open label
Not provided
PrEP
HIV
NCT07402044
https://clinicaltrials.gov/study/NCT07402044
Phase II
Not yet recruiting
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.
CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
Intervention 1
Not provided
Anticipated Start Date
2026-03-15
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2026-03-23
Estimated Primary Completion Date
2028-03-15
Estimated Completion Date
2028-03-15
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Not provided
Observational studies (incl. patient registries)
50
Non-randomized
Single group assignment
Not provided
Open label
Not provided
Treatment
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | Study on Long-Acting Cabotegravir and Lenacapavir for HIV Patients: Evaluating Dual Antiretroviral Therapy | https://clinicaltrials.eu/trial/study-on-long-acting-cabotegravir-and-lenacapavir-for-hiv-patients-evaluating-dual-antiretroviral-therapy/ |
NCT06488846
https://clinicaltrials.gov/study/NCT06488846
Marketed
Enrolling by invitation
University of California, San Francisco
This study will support the expansion of long-acting injectable antiretroviral therapy (LAI-ART) in non-clinical settings by developing, implementing, and evaluating a comprehensive, theory-informed training intervention to support the administration of LAI-ART by a trained layperson injector (e.g., friend, family, partner identified by a person living with HIV). This study will address barriers to LAI-ART uptake and persistence, enhance real-world effectiveness, and help close critical HIV care gaps.
Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home
Intervention 1
Intervention 2
Intervention 3
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2026-02-16
Anticipated Date of Last Follow-up
2026-04-29
Estimated Primary Completion Date
2027-06-30
Estimated Completion Date
2027-09-29
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Observational studies (incl. patient registries)
1000
Non-randomized
Not provided
Not provided
Open label
Not provided
Treatment
HIV
NCT05996471
https://clinicaltrials.gov/study/NCT05996471
Phase II
Active, not recruiting
ViiV Healthcare
The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV. VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results. The study will be conducted in 3 parts followed by a Long-Term Follow-up phase (LTFU).
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-08-17
Anticipated Date of Last Follow-up
2026-11-04
Estimated Primary Completion Date
Not provided
Estimated Completion Date
2028-11-09
Actual Primary Completion Date
2026-05-27
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Inclusion criteria Age 1. Participant must be 18 to 70 years of age inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics 2. Must be on uninterrupted current regimen for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (HIV-1 RNA ≥200 c/mL). Acceptable stable - ARV regimens prior to Screening include at least one NRTI plus: * INSTI * NNRTI * Boosted PI (or atazanavir \[ATV\] unboosted) * Excludes current use of cabotegravir or fostemsavir The addition, removal, or switch of a drug(s) that h
Interventional (clinical trial)
185
Randomized
Sequential assignment
Not provided
Open label
Not provided
Treatment
HIV
| Type | Title | Content | Link |
|---|---|---|---|
| Link | N6LS: 4-monthly injectable bNAb with monthly injectable cabotegravir | https://i-base.info/htb/50617 |
NCT05755204
https://clinicaltrials.gov/study/NCT05755204
Marketed
Terminated
Orlando Immunology Center
The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also include reasons for lack of retention in PrEP care)
A Pharmacist-run PrEP Program for Women
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-06-21
Anticipated Date of Last Follow-up
2025-02-12
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2024-10-15
Actual Completion Date
2024-10-15
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
No
Accepts healthy individuals
Yes
Not provided
Not provided
2
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
NCT03739996
https://clinicaltrials.gov/study/NCT03739996
Phase II
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this study was to assess the safety, tolerability, antiviral activity, and pharmacokinetics of long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma viremia.
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2019-12-31
Anticipated Date of Last Follow-up
2025-05-07
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2024-04-29
Actual Completion Date
2024-04-29
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
No
Step 1 Inclusion Criteria: * Individual with HIV-1 * On a three-drug ART regimen for at least 8 weeks that includes a boosted protease inhibitor (PI), a nonnuceloside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor (INSTI) plus two nuclesodie reverse transcriptase inhibitors (NRTI) with no history of switch due to virologic failure. * CD4+ cell count greater than or equal to 350 cells/mm\^3 * Virally suppressed (\< 50 copies/mL) within 2 years prior to study entry * Susceptibility to VRC07-523LS based on IC50 less than or equal to 0.25 ug/mL and a Maximum Percent Inhibition \> 98% using the Monogram PhenoSense Assay * Certain laboratory values obtained within 60 days prior to study entry and in an acceptable range * For participants of child-bearing potential: * A ne
Interventional (clinical trial)
75
Not provided
Single group assignment
Not provided
Open label
Not provided
Treatment
HIV
NCT03462810
https://clinicaltrials.gov/study/NCT03462810
Marketed
Active, not recruiting
ViiV Healthcare
The goal of this compassionate use program is to provide a mechanism to supply Cabotegravir, CAB on an individual named patient basis for treatment of individuals who have no available treatment alternatives and/or limited treatment options (e.g., who are unable to participate in the Phase III clinical studies or do not qualify), and are in need of new drugs to construct an effective antiviral regimen and may require the use of parenterally administered drug given underlying medical conditions. You can access ViiV's Policy on Compassionate via https://us.viivhealthcare.com/media/124424/viivs-external-policy-on-cup\_final-version\_23feb2017.pdf.
GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV
Intervention 1
Not provided
Anticipated Start Date
Not provided
Actual Start Date
Not provided
Anticipated Date of Last Follow-up
2021-05-19
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
NCT02462772
https://clinicaltrials.gov/study/NCT02462772
Phase II
Withdrawn
Centre for the AIDS Programme of Research in South Africa
The CAPRISA 014 trial aims to assess the safety and acceptability of the long-acting (LA) injectable antiretroviral agent, cabotegravir LA (GSK1265744), in HIV uninfected women in KwaZulu-Natal, South Africa.
Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa
Intervention 1
Intervention 2
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2015-10-01
Anticipated Date of Last Follow-up
2015-11-04
Estimated Primary Completion Date
2018-09-01
Estimated Completion Date
2018-09-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
No
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: * Able and willing to provide written informed consent to be screened for, and to enrol in, the study. * Able and willing to provide adequate locator information for study retention purposes. * Sexually active, defined as having had vaginal intercourse at least once in the past 30 days prior to screening. * HIV negative on testing performed by study staff * Have a negative pregnancy test performed by study staff * Agree to use a non-barrier form of contraceptive * Agree to adhere to study visits and procedures. * Haemoglobin \> 11 g/dL, * ALT \< ULN * AST \< ULN * Total bilirubin \< Grade 1 * Direct bilirubin \< ULN * Creatinine clearance ≥60 mL/min * Hepatitis B surface antigen (HBsAg) negative * Hepatitis C Ab negative * In general good health, as assessed clinically
Interventional (clinical trial)
Not provided
Randomized
Parallel Assignment
Not provided
Triple-blind masking
Not provided
PrEP
HIV
NCT01206920
https://clinicaltrials.gov/study/NCT01206920
Marketed
Recruiting
George Washington University
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for patients diagnosed with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) or at higher risk for acquiring HIV and receiving care in Washington, DC.
The DC Cohort Longitudinal HIV Status Neutral Study
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2011-01-01
Anticipated Date of Last Follow-up
2026-01-29
Estimated Primary Completion Date
2041-01-01
Estimated Completion Date
2041-01-01
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Unspecified
Not provided
Not provided
Not provided
19000
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
NCT04518228
https://clinicaltrials.gov/study/NCT04518228
Marketed
Terminated
National Institute of Allergy and Infectious Diseases (NIAID)
The purpose of this study was to evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Intervention 1
Intervention 2
Intervention 3
Intervention 4
Intervention 5
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2021-09-01
Anticipated Date of Last Follow-up
2026-08-03
Estimated Primary Completion Date
Not provided
Estimated Completion Date
Not provided
Actual Primary Completion Date
2025-04-24
Actual Completion Date
2025-07-10
Age Cohort
Genders
Accepts pregnant individuals
Yes
Accepts lactating individuals
Yes
Accepts healthy individuals
Yes
Not provided
Not provided
Not provided
205
Not provided
Not provided
Not provided
Not provided
Not provided
PrEP
HIV
No proprietary excipient used
No novel excipient or existing excipient used
No residual solvent used
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Cabotegravir crystalline forms
Expiry date: 2038-01-25 The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections. |
WO2018149608 | Polymorphs | Sandoz Ag | Yes |
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | ||
| Filed | ||
| Not in force | World Intellectual Property Organization (WIPO), China, Morocco, Albania, Serbia, Bosnia and Herzegovina, Montenegro, Türkiye, Moldova, Republic of, North Macedonia, Tunisia, Mexico | World Intellectual Property Organization (WIPO), Australia, Canada, Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Russian Federation, United States of America |
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Cabotegravir long-acting parenteral compositions
Expiry date: 2031-09-15 The present invention relates to pharmaceutical compositions of cabotegravir useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections. |
WO2012037320 | Composition | Glaxosmithkline Llc, Mundhra, Deepak B, Pan, Rennan, Viiv Healthcare Company | Yes |
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | ||
| Filed | ||
| Not in force | World Intellectual Property Organization (WIPO), Brazil, China, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Mexico, Ukraine, South Africa, India | World Intellectual Property Organization (WIPO), Australia, Canada, Chile, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, Israel, Japan, Korea, Republic of, Taiwan, Province of China, United States of America |
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Cabotegravir or dolutegravir processes and intermediates
Expiry date: 2031-03-22 Relates to the preparation of carbamoylpyridone derivatives and intermediates which are useful as HIV integrase inhibitors. |
WO2011119566 | Intermediate(s), Process | Glaxosmithkline Llc | Yes |
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | ||
| Filed | ||
| Not in force | World Intellectual Property Organization (WIPO), China, Albania, Serbia, Bosnia and Herzegovina, Montenegro, Türkiye, North Macedonia, India | World Intellectual Property Organization (WIPO), Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Japan, Korea, Republic of, Singapore, Taiwan, Province of China, United States of America |
| Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
|---|---|---|---|---|---|
|
Dolutegravir and Cabotegravir compounds
Expiry date: 2026-04-28 The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z<1> is NR<4>; R<1> is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R<2> is optionally substituted aryl; R<3> is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R<4> and Z<2> part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound. |
WO2006116764 | Compound | Glaxosmithkline Llc | Yes |
| Patent status/countries | Low, Low- middle and upper-middle | High income |
|---|---|---|
| Granted | Brazil, China, Morocco, Mexico, Philippines, Ukraine, Viet Nam, South Africa, Türkiye, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Republic of, Tajikistan, Turkmenistan, Nigeria, Colombia, Egypt, India, Indonesia, Malaysia, Algeria, World Intellectual Property Organization (WIPO) | United States of America, Australia, Canada, Hong Kong, Israel, Japan, Korea, Republic of, Luxembourg, Norway, New Zealand, Taiwan, Province of China, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Latvia, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Russian Federation, Trinidad and Tobago, World Intellectual Property Organization (WIPO), Singapore, Gibraltar, Guernsey, Jersey |
| Filed | ||
| Not in force |
Landovitz RJ — Lancet HIV — 2023-12-01
Link: https://pubmed.ncbi.nlm.nih.gov/37952550/
Summary: Long-acting injectable cabotegravir PrEP retained high efficacy for HIV prevention in men and transgender women who have sex with men during the first year of open-label follow-up, with a near-identical HR for HIV risk reduction between long-acting injectable cabotegravir and daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP during the first year after unblinding compared with the blinded period. Extended follow-up further defined the risk period for diagnostic delays and emergence of INSTI resistance.
Background: Injectable cabotegravir was superior to daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in two clinical trials. Both trials had the primary aim of establishing the HIV prevention efficacy of long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) compared with tenofovir disoproxil fumarate plus emtricitabine daily oral PrEP. Long-acting PrEP was associated with diagnostic delays and integrase strand-transfer inhibitor (INSTI) resistance. This report presents findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study.
Methods: The HPTN 083 randomised controlled trial enrolled HIV-uninfected cisgender men and transgender women at elevated HIV risk who have sex with men, from 43 clinical research sites in Africa, Asia, Latin America, and the USA. Inclusion criteria included: a negative HIV serological test at the screening and study entry, undetectable HIV RNA levels within 14 days of study entry, age 18 years or older, overall good health as determined by clinical and laboratory evaluations, and a creatinine clearance of 60 mL/min or higher. Participants were randomly allocated to receive long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP. After study unblinding, participants remained on their original regimen awaiting an extension study. HIV infections were characterised retrospectively at a central laboratory. Here we report the secondary analysis of efficacy and safety for the first unblinded year. The primary outcome was incident HIV infection. Efficacy analyses were done on the modified intention-to-treat population using a Cox regression model. Adverse events were compared across treatment groups and time periods (blinded vs unblinded). This trial is registered with ClinicalTrials.gov, NCT02720094.
Findings: Of the 4488 participants who contributed person-time to the blinded analysis, 3290 contributed person-time to the first unblinded year analysis between May 15, 2020, and May 14, 2021. Updated HIV incidence in the blinded phase was 0·41 per 100 person-years for long-acting injectable cabotegravir PrEP and 1·29 per 100 person-years for daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP (hazard ratio [HR] 0·31 [95% CI 0·17-0·58], p=0·0003). HIV incidence in the first unblinded year was 0·82 per 100 person-years for long-acting PrEP and 2·27 per 100 person-years for daily oral PrEP (HR 0·35 [0·18-0·69], p=0·002). Adherence to both study products decreased after study unblinding. Additional infections in the long-acting PrEP group included two with on-time injections; three with one or more delayed injections; two detected with long-acting PrEP reinitiation; and 11 more than 6 months after their last injection. Infection within 6 months of cabotegravir exposure was associated with diagnostic delays and INSTI resistance. Adverse events were generally consistent with previous reports; incident hypertension in the long-acting PrEP group requires further investigation.
Interpretation: Long-acting injectable cabotegravir PrEP retained high efficacy for HIV prevention in men and transgender women who have sex with men during the first year of open-label follow-up, with a near-identical HR for HIV risk reduction between long-acting injectable cabotegravir and daily oral tenofovir disoproxil fumarate plus emtricitabine PrEP during the first year after unblinding compared with the blinded period. Extended follow-up further defined the risk period for diagnostic delays and emergence of INSTI resistance.
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Delany-Moretlwe S — Lancet — 2022-05-07
Summary: cabotegravir was generally safe, well tolerated, and effective. Cabotegravir was superior to TDF-FTC in preventing HIV infection in women in HPTN084.
Background: Oral pre-exposure prophylaxis has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women experience considerable barriers to daily pill-taking, such as stigma, judgement, and the fear of violence. Safe and effective long-acting agents for HIV prevention are needed for women. We aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir diphosphate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women.
Methods: HPTN 084 was a phase 3, randomised, double-blind, double-dummy, active-controlled, superiority trial in 20 clinical research sites in seven countries in sub-Saharan Africa. Participants were eligible for enrolment if they were assigned female sex at birth, were aged 18-45 years, reported at least two episodes of vaginal intercourse in the previous 30 days, were at risk of HIV infection based on an HIV risk score, and agreed to use a long-acting reversible contraceptive method. Participants were randomly assigned (1:1) to either active cabotegravir with TDF-FTC placebo (cabotegravir group) or active TDF-FTC with cabotegravir placebo (TDF-FTC group). Study staff and participants were masked to study group allocation, with the exception of the site pharmacist who was responsible for study product preparation. Participants were prescribed 5 weeks of daily oral product followed by intramuscular injections every 8 weeks after an initial 4-week interval load, alongside daily oral pills. Participants who discontinued injections were offered open-label daily TDF-FTC for 48 weeks. The primary endpoints of the study were incident HIV infection in the intention-to-treat population, and clinical and laboratory events that were grade 2 or higher in all women who had received at least one dose of study product. This study is registered with ClinicalTrials.gov, NCT03164564.
Findings: From Nov 27, 2017, to Nov 4, 2020, we enrolled 3224 participants (1614 in the cabotegravir group and 1610 in the TDF-FTC group). Median age was 25 years (IQR 22-30); 1755 (54·7%) of 3209 had two or more partners in the preceding month. 40 incident infections were observed over 3898 person-years (HIV incidence 1·0% [95% CI 0·73-1·40]); four in the cabotegravir group (HIV incidence 0·2 cases per 100 person-years [0·06-0·52]) and 36 in the TDF-FTC group (1·85 cases per 100 person-years [1·3-2·57]; hazard ratio 0·12 [0·05-0·31]; p<0·0001; risk difference -1·6% [-1·0% to -2·3%]. In a random subset of 405 TDF-FTC participants, 812 (42·1%) of 1929 plasma samples had tenofovir concentrations consistent with daily use. Injection coverage was 93% of the total number of person-years. Adverse event rates were similar across both groups, apart from injection site reactions, which were more frequent in the cabotegravir group than in the TDF-FTC group (577 [38·0%] of 1519 vs 162 [10·7%] of 1516]) but did not result in injection discontinuation. Confirmed pregnancy incidence was 1·3 per 100 person-years (0·9-1·7); no congenital birth anomalies were reported.
Interpretation: Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women.
Bowers GD, — Xenobiotica — 2015-07-01
Link: https://doi.org/10.3109/00498254.2015.1060372
1. Cabotegravir [(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide] is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.
2. Metabolism, pharmacokinetics and excretion were investigated in healthy human subjects who received either a single oral dose (28.2 mg) of [14C]cabotegravir in a mass balance study, or LA formulations of unlabeled cabotegravir (200–800 mg), intramuscularly or subcutaneously, in a separate study. Metabolism, distribution and excretion of [14C]cabotegravir were also investigated in mice, rats and monkeys.
3. Recovery of radioactivity in humans represented a mean total of 85.3% of the dose, including 26.8% in the urine. The mean apparent terminal phase half-life was similar for both cabotegravir and radioactivity, 39 h compared to 41 h.
4. Following oral, intramuscular and subcutaneous administration, cabotegravir was the major component in plasma and the glucuronic acid conjugate (M1) represented the predominant component in urine. Cabotegravir was present in bile along with its major metabolite (M1).
5. The primary metabolite of [14C]cabotegravir in mouse, rat and monkey was the same as that in human. In vitro phenotyping experiments demonstrated that cabotegravir was metabolized by UDP-glucuronosyltransferase (UGT) 1A1 and UGT1A9.
Formulation and pharmacology of long-acting cabotegravir.
Trezza C — Curr Opin HIV AIDS — 2015-07-01
Link: https://pubmed.ncbi.nlm.nih.gov/26049948/
Purpose of review
Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence to a daily regimen. The present review will highlight the unique formulation properties and pharmacologic attributes of long-acting cabotegravir nanosuspension.
Recent findings
Cabotegravir is a potent integrase strand transfer inhibitor that has been formulated as an oral tablet for daily administration and as a long-acting injectable nanosuspension. Long-acting cabotegravir is readily absorbed following intramuscular and subcutaneous administration and has an elimination half-life of approximately 40 days, allowing for administration on a monthly or less frequent schedule. Repeat-dose pharmacokinetic studies and population pharmacokinetic modeling indicate monthly and bi-monthly dosing achieves clinically relevant plasma concentrations considered effective for HIV maintenance therapy and that quarterly injections are appropriate for investigation as preexposure prophylaxis. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase 1A1 and is unlikely to be impacted by the cytochrome P450 metabolic pathway. In vitro and in vivo data suggest cabotegravir has a low propensity to cause, or be subject to, significant drug interactions.
Summary
The pharmacologic profile of long-acting cabotegravir supports its continued development for both treatment and prevention of HIV-1 infection.
Spreen W — HIV Clin Trials — 2013-09-01
Link: https://doi.org/10.1310/hct1405-192
Background: GSK1265744 is an HIV integrase strand transfer inhibitor selected for clinical development.
Objective: This first-time-in-human and phase IIa investigation assessed GSK1265744 antiviral activity, pharmacokinetics, safety, and tolerability in healthy and HIV-1-infected subjects.
Methods: This double-blind, placebo-controlled study consisted of a dose escalation of single (part A) and multiple (part B) oral doses in 48 healthy subjects and an oral dose (part C) in 11 HIV-1-infected subjects. In part A, 2 cohorts of 9 subjects received either 5 and 25 mg or 10 and 50 mg. In part B, 3 cohorts of 10 subjects received 5, 10, or 25 mg once daily for 14 days. In part C and the phase IIa study, subjects received 5 or 30 mg once daily for 10 days.
Results: Dose-proportional increases in drug exposure were observed in healthy and HIV-1-infected subjects. In healthy subjects, pharmacokinetic variability was low following single or repeat dosing (coefficient of variation, 13%-34% and 15%-23%, respectively). Mean plasma half-life was 31.5 hours. GSK1265744 monotherapy significantly reduced plasma HIV-1 RNA from baseline to day 11 in HIV-1-infected subjects receiving 5 or 30 mg versus placebo (P < .001); mean decrease was 2.2 to 2.3 log10 copies/mL, respectively. Study drug was generally well tolerated with no clinically relevant trends in laboratory values, vital signs, or electrocardiograms.
Conclusions: GSK1265744 was well tolerated in healthy and HIV-1-infected subjects. Results demonstrate once-daily doses of 5 or 30 mg exceeded minimum target therapeutic concentrations and produced a significant reduction in plasma HIV-1 RNA viral load.
Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals
K. Brown ; EACS2025; Moderated ePoster; October 17 2025 ;MeP20.4.LB
J. Boles, et al. Cabotegravir Injections Are More Acceptable Than Lenacapavir Injections Following a Single Dose: Results From CLARITY, a Randomized Crossover Study of Long-Acting Injectable Antiretrovirals. Presented at the European AIDS Conference (EACS 2025), 15-18 October, Paris, FR.
Presented at the European AIDS Conference (EACS 2025), 15-18 October, Paris, FR.